BBH logo

VanEck Vectors Biotech ETF (BBH)

$247.78

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BBH

AUM

$504591221

P/E ratio

24.8

Dividend yield

0.3726%

Expense ratio

0.35%

Beta

0.69672

Price on BBH

Previous close

$248.82

Today's open

$248

Day's range

$246.08 - $249.27

52 week range

$179.25 - $263.74

Profile about BBH

show more

Headquarters

US

Exchange

NASDAQ Global Market

Issue type

Exchange-Traded Fund

BBH industries and sectors

Industries

Health

News on BBH

Should You Invest in the VanEck Biotech ETF (BBH)?

Launched on December 20, 2011, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

news source

Zacks Investment Research • Nov 17, 2026

news preview

Simplify Health Care ETF vs. VanEck Biotech ETF: One Critical Difference Could Shape Future Returns

Simplify Health Care ETF uses active management to invest across the broader healthcare industry. VanEck Biotech ETF concentrates on 25 biotechnology companies and carries a lower expense ratio.

news source

The Motley Fool • Nov 12, 2026

news preview

Democrats Sweep Midterms: What It Means For Pharma And Biotech Holdings (Stocks To Watch)

U.S. midterm results signal a "Blue Wave," with Democrats controlling both House and Senate, likely impacting healthcare policy and funding. Health insurers like UnitedHealth and CVS Health typically rebound after policy shocks; Oscar Health stands out for ACA-driven growth and innovation.

news source

Seeking Alpha • Nov 5, 2026

news preview

ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

news source

Zacks Investment Research • Oct 28, 2026

news preview

Why Healthcare ETFs Are Hovering Around One-Year Highs

Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.

news source

Zacks Investment Research • Oct 23, 2026

news preview

Biotech ETF (BBH) Hits New 52-Week High

For investors seeking momentum, VanEck Biotech ETF BBH is probably on the radar. The fund just hit a 52-week high and has risen 41.1% from its 52-week low price of $176.30/share.

news source

Zacks Investment Research • Oct 21, 2026

news preview

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund.

news source

The Motley Fool • Oct 10, 2026

news preview

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?

FHLC features a much lower expense ratio of 0.08% compared to 0.35% for BBH. BBH is a concentrated portfolio of just 26 stocks, while FHLC holds around 350 companies.

news source

The Motley Fool • Sep 24, 2026

news preview

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

news source

Zacks Investment Research • Sep 21, 2026

news preview

Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues

Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, ​reinforcing the biotech pipeline for the fall IPO window.

news source

Reuters • Sep 18, 2026

news preview

¹ Disclosures

Get started with M1

Invest in VanEck Vectors Biotech ETF

Open an M1 investment account to buy and sell VanEck Vectors Biotech ETF commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BBH on M1